Wedbush Reiterates Outperform Rating on Sutro Biopharma, Keeps $60 Target
Wedbush reiterated its Outperform rating and $60 price target on Sutro Biopharma. The target implies 470.3% upside from the Oct. 14 close of $10.52.
Wedbush reiterated its Outperform rating and $60 price target on Sutro Biopharma. The target implies 470.3% upside from the Oct. 14 close of $10.52.